Inhibikase Therapeutics, Inc. (IKT) Earnings History
Net Loss10 years of earnings data (2016–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Inhibikase Therapeutics, Inc. (IKT) Earnings Overview
As of July 8, 2026, Inhibikase Therapeutics, Inc. (IKT) reported trailing twelve-month net income of -$51M, reflecting +57.8% year-over-year growth. The company earned $-0.52 per diluted share over the past four quarters.
Looking at the long-term picture, IKT's historical earnings data spans multiple years. The company achieved its highest annual net income of -$436,075 in fiscal 2017.
Inhibikase Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including PRTA (-$151M net income, -2520.6% margin), ACAD ($376M net income, 36.5% margin), SAVA (-$106M net income), IKT has comparable earnings metrics. Compare IKT vs PRTA →
IKT Earnings vs Peers
Earnings metrics vs comparable public companies
IKT Historical Earnings Data (2016–2025)
10 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$48M | -75.4% | -$52M | $-0.49 | - | - |
| 2024 | -$28M | -44.6% | -$29M | $-1.16 | - | - |
| 2023 | -$19M | -5.4% | -$20M | $-3.57 | -7304.8% | -7712.0% |
| 2022 | -$18M | -22.1% | -$18M | $-4.26 | -14625.9% | -14686.2% |
| 2021 | -$15M | -419.2% | -$15M | $-4.88 | -476.9% | -476.2% |
| 2020 | -$3M | +50.2% | -$3M | $-1.72 | -407.7% | -403.5% |
| 2019 | -$6M | -165.9% | -$6M | $-3.34 | -509.7% | -507.5% |
| 2018 | -$2M | -393.6% | -$2M | $-1.61 | -53.3% | -52.5% |
| 2017 | $-436,075 | +30.6% | $-405,130 | $-0.25 | -21.2% | -19.7% |
| 2016 | $-628,737 | - | $-613,288 | $-0.48 | -65.0% | -63.4% |
Download Data
Export IKT earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
IKT — Frequently Asked Questions
Quick answers to the most common questions about buying IKT stock.
What is IKT earnings per share (EPS)?
IKT trailing twelve-month (TTM) diluted EPS is $-0.52, reflecting +57.8% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2016 to 2025 is available in the table on this page.
What is Inhibikase Therapeutics, Inc.'s net income?
Inhibikase Therapeutics, Inc. (IKT) trailing twelve-month net income is $-51M as of 2025. Earnings grew +57.8% year-over-year.
Is IKT profitable?
IKT is not currently profitable on a TTM basis, reporting a net loss of $-51M. Net margin is N/A. Investors should monitor for a return to profitability.
What is IKT's earnings growth rate?
IKT compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2016 to 2025.
What are IKT's profit margins?
Inhibikase Therapeutics, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -36.0%.
Is IKT growing earnings?
Yes, IKT earnings are accelerating — EPS growth of +57.8% exceeds the 5-year CAGR of N/A. TTM net income reached $-51M. Earnings momentum is strengthening.
What was IKT's best earnings year?
Inhibikase Therapeutics, Inc.'s highest annual net income on record is $-436075.00, achieved in fiscal year 2017. Earnings history on this page spans 2016 to 2025 and includes all annual and quarterly figures.
What were IKT's earnings last quarter?
IKT's most recent reported quarter was Q1 2026. Net income was $-16M with diluted EPS of $-0.17. For a full breakdown of all quarters, see the quarterly earnings table on this page.